Annual Cash & Cash Equivalents
$119.17 M
+$102.53 M+616.23%
March 31, 2024
Summary
- As of February 25, 2025, VTGN annual cash & cash equivalents is $119.17 million, with the most recent change of +$102.53 million (+616.23%) on March 31, 2024.
- During the last 3 years, VTGN annual cash & cash equivalents has risen by +$16.06 million (+15.57%).
- VTGN annual cash & cash equivalents is now at all-time high.
Performance
VTGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$74.72 M
-$9.53 M-11.31%
December 31, 2024
Summary
- As of February 25, 2025, VTGN quarterly cash and cash equivalents is $74.72 million, with the most recent change of -$9.53 million (-11.31%) on December 31, 2024.
- Over the past year, VTGN quarterly cash and cash equivalents has dropped by -$28.20 million (-27.40%).
- VTGN quarterly cash and cash equivalents is now -40.96% below its all-time high of $126.56 million, reached on December 31, 2023.
Performance
VTGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VTGN Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +616.2% | -27.4% |
| 3 y3 years | +15.6% | -27.4% |
| 5 y5 years | +809.6% | -27.4% |
VTGN Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +616.2% | -41.0% | +676.5% |
| 5 y | 5-year | at high | +8693.9% | -41.0% | +6926.7% |
| alltime | all time | at high | -100.0% | -41.0% | -100.0% |
VistaGen Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $74.72 M(-11.3%) |
| Sep 2024 | - | $84.25 M(-18.1%) |
| Jun 2024 | - | $102.92 M(-13.6%) |
| Mar 2024 | $119.17 M(+616.2%) | $119.17 M(-5.8%) |
| Dec 2023 | - | $126.56 M(+236.5%) |
| Sep 2023 | - | $37.61 M(+290.8%) |
| Jun 2023 | - | $9.62 M(-42.2%) |
| Mar 2023 | $16.64 M(-75.6%) | $16.64 M(-33.5%) |
| Dec 2022 | - | $25.04 M(-29.0%) |
| Sep 2022 | - | $35.29 M(-32.1%) |
| Jun 2022 | - | $51.99 M(-23.7%) |
| Mar 2022 | $68.14 M(-33.9%) | $68.14 M(-18.6%) |
| Dec 2021 | - | $83.70 M(-10.6%) |
| Sep 2021 | - | $93.63 M(-4.2%) |
| Jun 2021 | - | $97.78 M(-5.2%) |
| Mar 2021 | $103.11 M(+7508.9%) | $103.11 M(-1.2%) |
| Dec 2020 | - | $104.33 M(+577.5%) |
| Sep 2020 | - | $15.40 M(+896.2%) |
| Jun 2020 | - | $1.55 M(+14.1%) |
| Mar 2020 | $1.36 M(-89.7%) | $1.36 M(+27.4%) |
| Dec 2019 | - | $1.06 M(-73.9%) |
| Sep 2019 | - | $4.07 M(-50.9%) |
| Jun 2019 | - | $8.30 M(-36.7%) |
| Mar 2019 | $13.10 M(+26.2%) | $13.10 M(+108.4%) |
| Dec 2018 | - | $6.29 M(-19.7%) |
| Sep 2018 | - | $7.83 M(+8.3%) |
| Jun 2018 | - | $7.23 M(-30.3%) |
| Mar 2018 | $10.38 M(+255.3%) | $10.38 M(-20.4%) |
| Dec 2017 | - | $13.03 M(+638.6%) |
| Sep 2017 | - | $1.76 M(+8.4%) |
| Jun 2017 | - | $1.63 M(-44.3%) |
| Mar 2017 | $2.92 M | $2.92 M(-33.2%) |
| Dec 2016 | - | $4.37 M(-30.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $6.26 M(-26.4%) |
| Jun 2016 | - | $8.50 M(+1883.6%) |
| Mar 2016 | $428.50 K(+512.1%) | $428.50 K(-63.0%) |
| Dec 2015 | - | $1.16 M(+66.9%) |
| Sep 2015 | - | $694.00 K(+473.6%) |
| Jun 2015 | - | $121.00 K(+72.9%) |
| Mar 2015 | $70.00 K(>+9900.0%) | $70.00 K(+430.3%) |
| Dec 2014 | - | $13.20 K(>+9900.0%) |
| Sep 2014 | - | $0.00(-100.0%) |
| Jun 2014 | - | $400.70 K(>+9900.0%) |
| Mar 2014 | $0.00(-100.0%) | $0.00(-100.0%) |
| Dec 2013 | - | $20.70 K(+218.5%) |
| Sep 2013 | - | $6500.00(-92.8%) |
| Jun 2013 | - | $89.80 K(-85.9%) |
| Mar 2013 | $638.10 K(+687.8%) | $638.10 K(+2536.8%) |
| Dec 2012 | - | $24.20 K(+80.6%) |
| Sep 2012 | - | $13.40 K(-57.7%) |
| Jun 2012 | - | $31.70 K(-60.9%) |
| Mar 2012 | $81.00 K(+4400.0%) | $81.00 K(-51.3%) |
| Dec 2011 | - | $166.40 K(+76.1%) |
| Sep 2011 | - | $94.50 K(-90.0%) |
| Jun 2011 | - | $942.10 K(>+9900.0%) |
| Mar 2011 | - | $6100.00(+238.9%) |
| Dec 2010 | $1800.00(+200.0%) | $1800.00(-21.7%) |
| Sep 2010 | - | $2300.00(+21.1%) |
| Jun 2010 | - | $1900.00(-45.7%) |
| Mar 2010 | - | $3500.00(+483.3%) |
| Dec 2009 | $600.00(-97.2%) | $600.00(-80.0%) |
| Sep 2009 | - | $3000.00(+100.0%) |
| Jun 2009 | - | $1500.00(-93.1%) |
| Dec 2008 | $21.80 K | $21.80 K(>+9900.0%) |
| Jun 2008 | - | $200.00(-33.3%) |
| Mar 2008 | - | $300.00 |
FAQ
- What is VistaGen Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual cash & cash equivalents year-on-year change?
- What is VistaGen Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly cash and cash equivalents year-on-year change?
What is VistaGen Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of VTGN is $119.17 M
What is the all time high annual cash & cash equivalents for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual cash & cash equivalents is $119.17 M
What is VistaGen Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, VTGN annual cash & cash equivalents has changed by +$102.53 M (+616.23%)
What is VistaGen Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VTGN is $74.72 M
What is the all time high quarterly cash and cash equivalents for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly cash and cash equivalents is $126.56 M
What is VistaGen Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, VTGN quarterly cash and cash equivalents has changed by -$28.20 M (-27.40%)